Theravance Biopharma, Inc. is a biopharmaceutical company, which engages in the discovery, research, development, and commercialization of respiratory medicines. It operates through the U.S. and Europe geographical segments. Its products include telavancin under the VIBATIV brand, revefenacin under the TD 4208 brand, and neprilysin. The company was founded in July 2013 and is headquartered in George Town, Cayman Islands.
相关临床试验
54
1 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
1
1.9%
已完成
46
85.2%
终止
7
13.0%
暂无批准数据
- CRO acquisitions mid-trial create a 60-90 day high-friction period where TMF completeness can slip from 85-90% to below 70%, directly impacting FDA inspection readiness. - When sponsors are acquired after R&D downsizing, sites face 60-120 days of operational uncertainty with frozen budgets, unanswered invoices, and absent CRA contacts. - ICH E6(R3) and 21 CFR Part 312.52 require documented transfer-of-obligations agreements; sites must demand written confirmation of IND sponsor continuity during any transition. - Vertical integration of MSO and CRO functions under one parent entity raises GCP governance concerns that regulators are increasingly scrutinizing for monitoring independence.
- Theravance Biopharma's Phase 3 CYPRESS study evaluating ampreloxetine for neurogenic orthostatic hypotension in multiple system atrophy patients failed to meet its primary endpoint, leading to program termination. - The company is implementing a 60% cost reduction through organizational restructuring, including complete R&D wind-down and 50% workforce reduction, expected to save approximately $70 million annually. - Theravance's Strategic Review Committee is accelerating evaluation of value-maximizing alternatives, including potential company sale, while focusing on YUPELRI as its core commercial asset. - With $400 million expected cash at Q1 2026 end and projected $60-70 million annual cash flow from YUPELRI, the company maintains strong financial position despite clinical setback.
- Theravance Biopharma has completed enrollment in the pivotal Phase 3 CYPRESS study of ampreloxetine for neurogenic orthostatic hypotension in multiple system atrophy patients. - The investigational once-daily norepinephrine reuptake inhibitor could become the first therapy to provide durable benefit for 40,000 U.S. patients with this devastating condition. - Topline results are expected in Q1 2026, with plans for expedited NDA submission and priority FDA review if data prove supportive. - Previous Study 0170 showed a 72% reduction in treatment failure odds for MSA patients, demonstrating compelling symptom improvement without worsening supine hypertension.
- Multiple high-profile ANDA litigation settlements were resolved in the second and third quarters of 2025, involving major pharmaceutical companies and generic manufacturers across diverse therapeutic areas. - Settlement agreements typically resulted in patent validity acknowledgments and injunctions against generic manufacturers, with most claims dismissed without prejudice while allowing FDA approval processes to continue. - Notable settlements included complex multi-patent disputes for blockbuster drugs like Rinvoq, Jardiance, Xifaxan, and Biktarvy, demonstrating the ongoing importance of patent protection strategies in pharmaceutical innovation.
- China's NMPA has approved YUPELRI (revefenacin) as the first once-daily nebulized long-acting muscarinic antagonist for maintenance treatment of chronic obstructive pulmonary disease. - The regulatory approval triggers a $7.5 million milestone payment from Viatris to Theravance Biopharma, with additional sales milestones up to $37.5 million and tiered royalties of 14-20% on net sales. - Viatris assumes full responsibility for YUPELRI's launch and commercialization in China, while Theravance incurs no commercial costs in the region. - The approval strengthens Theravance's financial position, which includes $131 million in cash and potential near-term milestone payments from multiple revenue streams.
- New analyses from Theravance Biopharma's Phase 3 trials demonstrate ampreloxetine's selective mechanism of action and durable target engagement in treating neurogenic orthostatic hypotension (nOH) in multiple system atrophy patients. - Ampreloxetine showed no worsening of supine hypertension during ambulatory blood pressure monitoring, potentially addressing a significant safety concern with current FDA-approved treatments for orthostatic hypotension. - MSA patients treated with ampreloxetine experienced a 79% increase in plasma norepinephrine levels and sustained improvements in orthostatic blood pressure, with a 72% reduction in odds of treatment failure compared to placebo.
• The Janus Kinase (JAK) inhibitor pipeline is actively being developed by multiple companies, showing promise in treating various autoimmune and inflammatory diseases. • Key companies such as Incyte, AbbVie, and Bristol Myers Squibb are advancing JAK inhibitor therapies through clinical trials and regulatory submissions. • Emerging therapies like povorcitinib, upadacitinib, and deucravacitinib have demonstrated efficacy in treating conditions like hidradenitis suppurativa, axial spondyloarthritis, and plaque psoriasis. • The JAK inhibitor market is driven by the rising prevalence of chronic diseases and substantial investments in research and development, offering targeted treatment approaches.
